Review




Structured Review

Genechem control plasmids
Control Plasmids, supplied by Genechem, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/control plasmids/product/Genechem
Average 86 stars, based on 1 article reviews
control plasmids - by Bioz Stars, 2026-05
86/100 stars

Images



Similar Products

93
Sino Biological expression plasmid pcmv3 msnx10 ha
Expression Plasmid Pcmv3 Msnx10 Ha, supplied by Sino Biological, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/expression plasmid pcmv3 msnx10 ha/product/Sino Biological
Average 93 stars, based on 1 article reviews
expression plasmid pcmv3 msnx10 ha - by Bioz Stars, 2026-05
93/100 stars
  Buy from Supplier

97
New England Biolabs purexpress dhfr control plasmid
Purexpress Dhfr Control Plasmid, supplied by New England Biolabs, used in various techniques. Bioz Stars score: 97/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/purexpress dhfr control plasmid/product/New England Biolabs
Average 97 stars, based on 1 article reviews
purexpress dhfr control plasmid - by Bioz Stars, 2026-05
97/100 stars
  Buy from Supplier

96
Addgene inc undiluted control virus
Undiluted Control Virus, supplied by Addgene inc, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/undiluted control virus/product/Addgene inc
Average 96 stars, based on 1 article reviews
undiluted control virus - by Bioz Stars, 2026-05
96/100 stars
  Buy from Supplier

95
Santa Cruz Biotechnology control double nickase plasmid
Control Double Nickase Plasmid, supplied by Santa Cruz Biotechnology, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/control double nickase plasmid/product/Santa Cruz Biotechnology
Average 95 stars, based on 1 article reviews
control double nickase plasmid - by Bioz Stars, 2026-05
95/100 stars
  Buy from Supplier

98
Addgene inc control plasmid with pspax2
Control Plasmid With Pspax2, supplied by Addgene inc, used in various techniques. Bioz Stars score: 98/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/control plasmid with pspax2/product/Addgene inc
Average 98 stars, based on 1 article reviews
control plasmid with pspax2 - by Bioz Stars, 2026-05
98/100 stars
  Buy from Supplier

96
Addgene inc aav dio mcherry control
( A ) Experimental timeline. AAV vectors were injected into the nodose ganglion (NG) 28 days before the forced mouth-opening (FMO) procedure. FMO was performed for 3 h per day across five consecutive days. Facial mechanical thresholds (von Frey), grimace scores (MGS), and open-field activity were assessed at baseline and multiple time points after FMO. C21 was administered intraperitoneally once daily for 2 days beginning on day 1 post-FMO, and conditioned place-preference (CPP) testing was conducted between days 9–13 post-FMO. ( B ) Representative confocal fluorescence images of NG showing mCherry reporter expression following viral infection, with nuclei counterstained with DAPI. ( C ) Facial withdrawal thresholds across different Cre lines and wild-type after FMO. C21 was administered intraperitoneally after von Frey testing once daily on day 1 and 2 after FMO. Cre-driver mice received nodose ganglion injection of AAV-DIO-hM3Dq and control mice received <t>AAV-DIO-mCherry,</t> both received intraperitoneal C21 after injection. ( D ) Facial withdrawal thresholds in DAT-Cre mice or wild type mice with or without intra-TMJ injection of C21. DAT-cre mice received nodose ganglion injection of AAV-DIO-hM3Dq, followed by intra-TMJ injection of C21 or vehicle. Data are presented as mean ± s.e.m.: *p < 0.05, **p < 0.01, ***p < 0.001 (two-way ANOVA followed by Tukey’s multiple-comparisons test). ( E ) Representative facial images of WT and DAT-Cre mice before and after FMO with or without C21 treatment. ( F ) Quantification of spontaneous pain using the Mouse Grimace Scale (MGS). DAT-Cre + C21 mice exhibited significantly reduced MGS scores on day 5 and day 7 post-FMO compared to control groups. Data are mean ± s.e.m.; **p < 0.01, ***p < 0.001, ###p < 0.001 (two-way ANOVA followed by Tukey’s multiple-comparisons test).
Aav Dio Mcherry Control, supplied by Addgene inc, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/aav dio mcherry control/product/Addgene inc
Average 96 stars, based on 1 article reviews
aav dio mcherry control - by Bioz Stars, 2026-05
96/100 stars
  Buy from Supplier

86
Genechem control plasmids
( A ) Experimental timeline. AAV vectors were injected into the nodose ganglion (NG) 28 days before the forced mouth-opening (FMO) procedure. FMO was performed for 3 h per day across five consecutive days. Facial mechanical thresholds (von Frey), grimace scores (MGS), and open-field activity were assessed at baseline and multiple time points after FMO. C21 was administered intraperitoneally once daily for 2 days beginning on day 1 post-FMO, and conditioned place-preference (CPP) testing was conducted between days 9–13 post-FMO. ( B ) Representative confocal fluorescence images of NG showing mCherry reporter expression following viral infection, with nuclei counterstained with DAPI. ( C ) Facial withdrawal thresholds across different Cre lines and wild-type after FMO. C21 was administered intraperitoneally after von Frey testing once daily on day 1 and 2 after FMO. Cre-driver mice received nodose ganglion injection of AAV-DIO-hM3Dq and control mice received <t>AAV-DIO-mCherry,</t> both received intraperitoneal C21 after injection. ( D ) Facial withdrawal thresholds in DAT-Cre mice or wild type mice with or without intra-TMJ injection of C21. DAT-cre mice received nodose ganglion injection of AAV-DIO-hM3Dq, followed by intra-TMJ injection of C21 or vehicle. Data are presented as mean ± s.e.m.: *p < 0.05, **p < 0.01, ***p < 0.001 (two-way ANOVA followed by Tukey’s multiple-comparisons test). ( E ) Representative facial images of WT and DAT-Cre mice before and after FMO with or without C21 treatment. ( F ) Quantification of spontaneous pain using the Mouse Grimace Scale (MGS). DAT-Cre + C21 mice exhibited significantly reduced MGS scores on day 5 and day 7 post-FMO compared to control groups. Data are mean ± s.e.m.; **p < 0.01, ***p < 0.001, ###p < 0.001 (two-way ANOVA followed by Tukey’s multiple-comparisons test).
Control Plasmids, supplied by Genechem, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/control plasmids/product/Genechem
Average 86 stars, based on 1 article reviews
control plasmids - by Bioz Stars, 2026-05
86/100 stars
  Buy from Supplier

93
Addgene inc vector control plants
( A ) Experimental timeline. AAV vectors were injected into the nodose ganglion (NG) 28 days before the forced mouth-opening (FMO) procedure. FMO was performed for 3 h per day across five consecutive days. Facial mechanical thresholds (von Frey), grimace scores (MGS), and open-field activity were assessed at baseline and multiple time points after FMO. C21 was administered intraperitoneally once daily for 2 days beginning on day 1 post-FMO, and conditioned place-preference (CPP) testing was conducted between days 9–13 post-FMO. ( B ) Representative confocal fluorescence images of NG showing mCherry reporter expression following viral infection, with nuclei counterstained with DAPI. ( C ) Facial withdrawal thresholds across different Cre lines and wild-type after FMO. C21 was administered intraperitoneally after von Frey testing once daily on day 1 and 2 after FMO. Cre-driver mice received nodose ganglion injection of AAV-DIO-hM3Dq and control mice received <t>AAV-DIO-mCherry,</t> both received intraperitoneal C21 after injection. ( D ) Facial withdrawal thresholds in DAT-Cre mice or wild type mice with or without intra-TMJ injection of C21. DAT-cre mice received nodose ganglion injection of AAV-DIO-hM3Dq, followed by intra-TMJ injection of C21 or vehicle. Data are presented as mean ± s.e.m.: *p < 0.05, **p < 0.01, ***p < 0.001 (two-way ANOVA followed by Tukey’s multiple-comparisons test). ( E ) Representative facial images of WT and DAT-Cre mice before and after FMO with or without C21 treatment. ( F ) Quantification of spontaneous pain using the Mouse Grimace Scale (MGS). DAT-Cre + C21 mice exhibited significantly reduced MGS scores on day 5 and day 7 post-FMO compared to control groups. Data are mean ± s.e.m.; **p < 0.01, ***p < 0.001, ###p < 0.001 (two-way ANOVA followed by Tukey’s multiple-comparisons test).
Vector Control Plants, supplied by Addgene inc, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/vector control plants/product/Addgene inc
Average 93 stars, based on 1 article reviews
vector control plants - by Bioz Stars, 2026-05
93/100 stars
  Buy from Supplier

Image Search Results


( A ) Experimental timeline. AAV vectors were injected into the nodose ganglion (NG) 28 days before the forced mouth-opening (FMO) procedure. FMO was performed for 3 h per day across five consecutive days. Facial mechanical thresholds (von Frey), grimace scores (MGS), and open-field activity were assessed at baseline and multiple time points after FMO. C21 was administered intraperitoneally once daily for 2 days beginning on day 1 post-FMO, and conditioned place-preference (CPP) testing was conducted between days 9–13 post-FMO. ( B ) Representative confocal fluorescence images of NG showing mCherry reporter expression following viral infection, with nuclei counterstained with DAPI. ( C ) Facial withdrawal thresholds across different Cre lines and wild-type after FMO. C21 was administered intraperitoneally after von Frey testing once daily on day 1 and 2 after FMO. Cre-driver mice received nodose ganglion injection of AAV-DIO-hM3Dq and control mice received AAV-DIO-mCherry, both received intraperitoneal C21 after injection. ( D ) Facial withdrawal thresholds in DAT-Cre mice or wild type mice with or without intra-TMJ injection of C21. DAT-cre mice received nodose ganglion injection of AAV-DIO-hM3Dq, followed by intra-TMJ injection of C21 or vehicle. Data are presented as mean ± s.e.m.: *p < 0.05, **p < 0.01, ***p < 0.001 (two-way ANOVA followed by Tukey’s multiple-comparisons test). ( E ) Representative facial images of WT and DAT-Cre mice before and after FMO with or without C21 treatment. ( F ) Quantification of spontaneous pain using the Mouse Grimace Scale (MGS). DAT-Cre + C21 mice exhibited significantly reduced MGS scores on day 5 and day 7 post-FMO compared to control groups. Data are mean ± s.e.m.; **p < 0.01, ***p < 0.001, ###p < 0.001 (two-way ANOVA followed by Tukey’s multiple-comparisons test).

Journal: bioRxiv

Article Title: Vagal dopaminergic afferents link interoception to trigeminal pain modulation

doi: 10.64898/2026.03.27.714928

Figure Lengend Snippet: ( A ) Experimental timeline. AAV vectors were injected into the nodose ganglion (NG) 28 days before the forced mouth-opening (FMO) procedure. FMO was performed for 3 h per day across five consecutive days. Facial mechanical thresholds (von Frey), grimace scores (MGS), and open-field activity were assessed at baseline and multiple time points after FMO. C21 was administered intraperitoneally once daily for 2 days beginning on day 1 post-FMO, and conditioned place-preference (CPP) testing was conducted between days 9–13 post-FMO. ( B ) Representative confocal fluorescence images of NG showing mCherry reporter expression following viral infection, with nuclei counterstained with DAPI. ( C ) Facial withdrawal thresholds across different Cre lines and wild-type after FMO. C21 was administered intraperitoneally after von Frey testing once daily on day 1 and 2 after FMO. Cre-driver mice received nodose ganglion injection of AAV-DIO-hM3Dq and control mice received AAV-DIO-mCherry, both received intraperitoneal C21 after injection. ( D ) Facial withdrawal thresholds in DAT-Cre mice or wild type mice with or without intra-TMJ injection of C21. DAT-cre mice received nodose ganglion injection of AAV-DIO-hM3Dq, followed by intra-TMJ injection of C21 or vehicle. Data are presented as mean ± s.e.m.: *p < 0.05, **p < 0.01, ***p < 0.001 (two-way ANOVA followed by Tukey’s multiple-comparisons test). ( E ) Representative facial images of WT and DAT-Cre mice before and after FMO with or without C21 treatment. ( F ) Quantification of spontaneous pain using the Mouse Grimace Scale (MGS). DAT-Cre + C21 mice exhibited significantly reduced MGS scores on day 5 and day 7 post-FMO compared to control groups. Data are mean ± s.e.m.; **p < 0.01, ***p < 0.001, ###p < 0.001 (two-way ANOVA followed by Tukey’s multiple-comparisons test).

Article Snippet: For selective activation of dopaminergic vagal neurons, AAV-DIO-hM3Dq (#44361; Addgene) or AAV-DIO-mCherry (control) (#50459; Addgene) was injected unilaterally into the right nodose ganglion of Cre-driver mice.

Techniques: Injection, Activity Assay, Conditioned Place Preference, Fluorescence, Expressing, Infection, Control